KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Zimmer Biomet Holdings (ZBH) EBIAT (2016 - 2026)

Zimmer Biomet Holdings has reported EBIAT over the past 18 years, most recently at $238.1 million for Q1 2026.

  • For Q1 2026, EBIAT rose 30.82% year-over-year to $238.1 million; the TTM value through Mar 2026 reached $761.7 million, down 16.74%, while the annual FY2025 figure was $705.1 million, 22.11% down from the prior year.
  • EBIAT for Q1 2026 was $238.1 million at Zimmer Biomet Holdings, up from $139.3 million in the prior quarter.
  • Over five years, EBIAT peaked at $420.3 million in Q4 2023 and troughed at -$130.5 million in Q4 2022.
  • A 5-year average of $182.7 million and a median of $194.0 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: plummeted 221.43% in 2022 and later soared 1537.32% in 2023.
  • Year by year, EBIAT stood at -$130.5 million in 2022, then skyrocketed by 422.07% to $420.3 million in 2023, then tumbled by 42.68% to $240.9 million in 2024, then plummeted by 42.18% to $139.3 million in 2025, then surged by 70.93% to $238.1 million in 2026.
  • Business Quant data shows EBIAT for ZBH at $238.1 million in Q1 2026, $139.3 million in Q4 2025, and $230.9 million in Q3 2025.